Intranasal delivery of dimethyl fumarate and monomethyl fumarate using hyaluronic acid-based hybrid nanoparticles to enhance CNS bioavailability
Authors:
- Carla SerriCSCarla Serri
- Massimo CossuMCMassimo Cossu
- Vincenzo GuarinoVincenzo Guarino
- Iriczalli Cruz-MayaICIriczalli Cruz-Maya
- Giada BottiGBGiada Botti
- Luca FerraroLFLuca Ferraro
- Paolo GiunchediPGPaolo Giunchedi
- Giovanna RassuGiovanna Rassu
- Elisabetta GaviniEGElisabetta Gavini
- Alessandro DalpiazADAlessandro Dalpiaz
Open Access
- 5 October 2025
- journal article
- Published by Elsevier in Journal of Drug Delivery Science and Technology
- Vol. 114
Abstract
No abstract availableThis publication has 56 references indexed in Scilit:
- Drug delivery to the brain via the nasal route of administration: exploration of key targets and major consideration factorsJournal of Pharmaceutical Investigation, 2022
- Pharmacokinetics and Bioavailability of Monomethyl Fumarate Following a Single Oral Dose of Bafiertam™ (Monomethyl Fumarate) or Tecfidera® (Dimethyl Fumarate)CNS Drugs, 2021
- Diagnosis and Treatment of Multiple SclerosisJAMA, 2021
- Stability indicating RP‐HPLC method for determination of dimethyl fumarate in presence of its main degradation products: Application to degradation kineticsJournal of Separation Science, 2020
- Insight into the mechanism of action of dimethyl fumarate in multiple sclerosisJournal of Molecular Medicine, 2019
- Carboxylesterases in lipid metabolism: from mouse to humanProtein & Cell, 2017
- Dimethyl Fumarate for Treatment of Multiple Sclerosis: Mechanism of Action, Effectiveness, and Side EffectsCurrent Neurology and Neuroscience Reports, 2013
- Detection of fumarate–glutathione adducts in the portal vein blood of rats: evidence for rapid dimethylfumarate metabolismArchives of Dermatological Research, 2013
- Physical and chemical stability of drug nanoparticlesAdvanced Drug Delivery Reviews, 2011
- Protein size and cerebrospinal fluid compositionJournal of Molecular Medicine, 1974